18F-fluorodeoxyglucose PET/CT imaging was performed from the skull base to the upper thigh at 50–70 min after intravenous administration of 5.2–7.4 MBq/kg (0.14–0.2 mCi/kg) of 18F-fluorodeoxyglucose22 (link). The median blood glucose level before 18F-fluorodeoxyglucose injection was 102 mg/dl (IQR 94–109). Two board-certified nuclear medicine physicians who were blinded to patient outcomes drew a volume of interest on the primary breast cancer or metastatic lymph nodes and assessed the maximum SUV of 18F-fluorodeoxyglucose uptake. The maximum standardized uptake values were harmonized across various PET/CT scanners (Biograph Sensation 16 and Biograph TruePoint 40, Siemens Healthineers, Knoxville, TN, USA; Discovery STE 8, Discovery PET/CT 690, and Discovery PET/CT 710, GE Healthcare, Milwaukee, WI, USA) without partial volume correction23 (link). The recovery coefficient profiles of variable-sized hot cylinders of the American College of Radiology-approved PET phantoms (i.e., Esser phantom) were matched24 (link),25 (link). Annual 18F water cylinder phantom-based cross-calibration between PET and dose calibrator assured the uniform standardized uptake value of 1.0 between PET scanners25 (link).
Free full text: Click here